Indraneel Mittra

Indraneel Mittra
Born (1943-06-28) 28 June 1943
New Delhi, India
Alma materDelhi University
Royal College of Surgeons of England
London University
Scientific career
FieldsCancer surgery

Laboratory science

Public health research
Academic advisors
Israel Doniach; Renato Dulbecco

Indraneel Mittra (born 28 June 1943) is an Indian cancer surgeon, basic research scientist, and public health researcher.[1] He is the Dr. Ernest Borges Chair in Translational Research and Professor Emeritus in the Department of Surgical Oncology, Tata Memorial Centre (TMC) in Mumbai.[1]

Biography

Mittra was born in New Delhi in 1943 to a family of doctors, with both his father and grandfather being physicians. Mittra studied medicine at the Maulana Azad Medical College, University of Delhi and graduated in 1965.[2] He received his surgical training in the UK at the Hammersmith Hospital and Royal Postgraduate Medical School, Royal Sussex County Hospital, and Guy's Hospital in London.[2] He subsequently became a Fellowship of the Royal Colleges of Surgeons of England in 1971,[2] and received his PhD in Medicine (cancer biology) from the University of London in 1977[2] under the guidance of Israel Doniach. He then completed his post-doctoral training under Renato Dulbecco at the Imperial Cancer Research Fund Laboratories in London.[2] He followed this up with a stint at St Bartholomew's Hospital and the Institute of Cancer Research in London as a Post-doctoral Fellow.[2]

Career and Research

Surgical and Clinical Research

On returning to India in 1982, Mittra joined the Tata Memorial Centre as a consultant surgical oncologist and quickly rose to become Professor of Surgery and Chief of the Surgical Breast Cancer Service. Realising the urgent need for science-based treatment of cancer, he pioneered the discipline of clinical research in India by introducing clinical research methodologies and the discipline of randomised clinical trials. He set up India's first multi-disciplinary breast cancer unit, a model which has since been adopted by most centres in the country.[1] The unit he set up was the first to make breast conservation surgery the standard treatment for early breast cancer.[3]

Public Health Research

In 1996, Mittra was the first Indian recipient of a RO1 grant from the United States National Institutes of Health (NIH). This award enabled him to conduct one of the largest community-based randomized trials on the use of low-cost technology for the early detection of breast and cervical cancer. This landmark screening study, involving 150,000 participants and lasting 20 years, showed that simple techniques conducted by trained health workers, viz., clinical breast examination (CBE) and visual inspection of the cervix after application of 4% acetic acid (VIA), can significantly reduce mortality from breast and cervical cancer, respectively. The results of this study, published in the British Medical Journal, showed that CBE was particularly effective in women above the age of 50, reducing death rate from breast cancer by 30%.[4][5][6][7] VIA reduced cervical cancer mortality by 30% in women of all ages.[8] These techniques are now cornerstones of the national cancer screeningprogram in India.[9] Implemented globally, they have the potential to save the lives of thousands of women in low- and middle-income countries and improve the well-being of countless others.

Translational Research

Mittra's first publication, a single-author paper in Nature when he was just 31, opened up research into the role of thyroid hormone in breast cancer.[10] Following his return to India, he worked extensively on prognostic factors in breast cancer and their relationship with treatment outcomes.[11][12]

For the past 25 years, Mittra's research has focused on cell-free chromatin particles (cfChPs), fragments of DNA that are released by dying cells, and their myriad biological activities. Mittra has demonstrated that when cfChPs enter healthy cells, they can damage the cells’ DNA, triggering biological changes associated with aging[13] and age-related diseases, sepsis,[14][15] the spread of cancer,[16] and the toxic side-effects of chemotherapy and radiotherapy.[17] He has also identified a potential treatment.[18] He has shown that when two simple nutraceuticals, copper and resveratrol, are mixed together, they generate oxygen radicals that can deactivate or neutralize cfChPs.[18][19] In small studies of patients with glioblastoma and squamous cell carcinoma, these nutraceuticals had a profound effect on tumour biology and may have halted disease growth and spread.[20]

Fundamental Research

His recent significant work involving cfChPs challenges the long-standing view of the mammalian genome as a stable, vertically inherited entity. It shows that cfChPs released from dying cells can enter living cells, assemble into concatemers, and function as autonomous "satellite genomes" capable of replication, transcription, and protein synthesis. These findings provide experimental evidence for horizontal gene transfer in mammals and reveal cfChPs as active biological agents rather than inert debris. The proposed binarygenome model suggests that inherited and acquired genomic elements coexist within cells, redefining genome plasticity, the role of non-coding DNA, and mechanisms underlying genomic innovation, cellular communication, and evolutionary change. Simply put, this work rewrites the rules of mammalian evolution and genomics.[21][22][23]

Awards and recognition

Mittra was elected to the fellowship of the Indian Academy of Sciences[1] and Indian National Science Academy[1] in recognition of his contribution to the field of cancer. He held the Pearce Goulde professorship at University College London (1999).[1]

Mittra has been on the editorial/advisory boards of The British Medical Journal, The Lancet Oncology, Nature Clinical Practice Oncology (currently Nature Reviews Clinical Oncology), the British Journal of Cancer, European Journal of Cancer, among others.[1] He holds a US patent (no. US 9,096,655 B2) titled "Method for in-vivo binding of chromatin fragments".[24]

References

  1. 1 2 3 4 5 6 7 "Indian Fellows – Indian National Science Academy". Retrieved 2023-08-09.
  2. 1 2 3 4 5 6 "ORCID". orcid.org. Retrieved 2023-08-11.
  3. ↑ Badwe RA, et al. Conservative surgery in breast cancer. Indian Journal of Surgery, (ISSN: 0972-2068) Vol 65 Num 4, 2003
  4. ↑ Mittra, Indraneel, et al. "Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai." Br. Med. J. 372 (2021).
  5. ↑ Wangchuk, Rinchen Norbu (2021-03-31). "Indian Surgeon's Groundbreaking Cancer Research Has Saved 1000s of Lives". The Better India.
  6. ↑ Abraham, Jame; MD; FACP (April 10, 2021). "Breast Cancer Screening With Clinical Breast Examination in Low- and Middle-Income Countries - The ASCO Post". ascopost.com. Retrieved 2023-08-17.
  7. ↑ "World's largest trial on breast cancer screening: The backstory". The Times of India. ISSN 0971-8257. Retrieved 2023-08-17.
  8. ↑ Shastri, Surendra S., et al. "Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India." Journal of the National Cancer Institute 106.3 (2014): dju009.
  9. ↑ Oswal K, et al. “Current Status of Implementation of Cancer Screening Programme in India: A Review of Policies and Practice.” Asian Pacific Journal of Cancer Prevention, 2025.
  10. ↑ Mittra, I. (April 1974). "Mammotropic effect of prolactin enhanced by thyroidectomy". Nature. 248 (5448): 525–526. Bibcode:1974Natur.248..525M. doi:10.1038/248525a0. ISSN 1476-4687. PMID 4824351. S2CID 4265881.
  11. ↑ 11. Mittra, Indraneel; MacRae, Kenneth D. (1991-12-01). "A meta-analysis of reported correlations between prognostic factors in breast cancer: Does axillary lymph node metastasis represent biology or chronology?". European Journal of Cancer and Clinical Oncology. 27 (12): 1574–1583. doi:10.1016/0277-5379(91)90418-D. ISSN 0277-5379. PMID 1838260.
  12. ↑ Mittra, Indraneel (January 1993). "Axillary lymph node metastasis in breast cancer: Prognostic indicator or lead-time bias?". European Journal of Cancer. 29 (3): 300–302. doi:10.1016/0959-8049(93)90371-l. ISSN 0959-8049. PMID 8398321.
  13. ↑ “Could a combination of two simple nutraceuticals slow down ageing disorders?” Research Features. November 24, 2023.
  14. ↑ Lorianpayne (2021-02-25). "How cell-free chromatin particles could be the missing link to the long-awaited treatment of sepsis". Research Features. Retrieved 2023-08-17.
  15. ↑ "Scientists uncover key molecular mechanism underlying different aspects of sepsis". News-Medical.net. 2020-03-27. Retrieved 2023-08-17.
  16. ↑ Malathy Iyer “Dying cancer cells, at times, trigger new tumours, say Tata doctors”. Feb 27, 2024,
  17. ↑ Helleday, T. (2017). "Chemotherapy-induced toxicity—a secondary effect caused by released DNA?". Annals of Oncology. 28 (9): 2054–2055. doi:10.1093/annonc/mdx349. ISSN 0923-7534. PMID 28911088.
  18. 1 2 Cancer (ACTREC), Advanced Centre for Treatment, Research & Education in. "Indian Researchers from ACTREC Discover Novel Therapeutic Agent for a Host of Diseases". www.prnewswire.com (Press release). Retrieved 2023-08-17.
  19. ↑ “Exploiting the synergy of nutraceuticals for cancer prevention and treatment”. EurekAlert News Release, 16-Jan-2023.
  20. ↑ “Can a combination of two simple nutraceuticals heal one of the deadliest brain cancers?”. EurekAlert. Feature Story, 9-Oct-2025
  21. ↑ “How Uptake of DNA Fragments from Dying Cells Could Transform Mammalian Evolution and Genomics”. Bioengineer. October 27, 2025.
  22. ↑ “Uptake of DNA fragments from dying cells could redefine mammalian evolution and genomics”. Eurekalert. Feature Story, 25-Sep-2025.
  23. ↑ “DNA Fragment Uptake May Redefine Mammal Evolution”. Mirage News. 25 Sep 2025.
  24. ↑ US 9096655, Mittra, Indraneel; Ramesan, RekhaMannemcherril& Sharma, Chandra Prakash et al., "Method for in-vivo binding of chromatin fragments", published 2015-08-04, assigned to Tata Memorial Centre.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.